The semaglutide complete guide: Wegovy, Ozempic, Rybelsus, and the oral form, organized

Semaglutide is the older of the two GLP-1 mainstays in current use and the one most people in your life will have heard of by brand name. Wegovy for weight management, Ozempic for diabetes, Rybelsus as the original oral pill, and as of late 2025, oral Wegovy at the 25mg dose. Same molecule, four very different products, very different supply states, very different prices.

This is the index. Every Panya post on semaglutide, organized by the question you're probably trying to answer.

You are choosing between Wegovy and tirzepatide

This is the most-asked decision in the catalog and the answer has shifted as more head-to-head data has accumulated.

Semaglutide vs tirzepatide is the comparison post. Mechanism difference (GLP-1 mono-agonist vs GLP-1 + GIP dual), efficacy (tirzepatide modestly higher in head-to-head), side-effect profile (similar but tirzepatide slightly more GI in week one), pricing (region-dependent).

Tirzepatide vs semaglutide covers the same comparison from a decision-frame angle rather than mechanism.

If you've been on semaglutide and are considering the switch, switching from semaglutide to tirzepatide covers the receptor math, washout question, and dose ceiling realism.

You're trying to understand the brand differences

Wegovy, Ozempic, and Rybelsus are different products with different approvals and different supply states.

Wegovy: branded for weight management, FDA approved 2021, doses up to 2.4mg weekly. The high-dose semaglutide product.

Ozempic: branded for type 2 diabetes, FDA approved 2017, doses up to 2.0mg weekly. Most off-label weight-loss prescribing in the US went through this product before Wegovy launched.

Rybelsus: oral semaglutide, FDA approved 2019 for T2D, taken daily. Lower bioavailability than the injectable. Requires fasting administration.

Oral Wegovy (25mg pill): late 2025 approval, available January 2026. Higher dose than Rybelsus, intended for weight management.

The post that maps the decision: insurance might cover Wegovy not Mounjaro covers the US insurance angle which often determines the brand choice. Insurance GLP-1 weight loss US is the broader insurance landscape.

You're shopping by region

Semaglutide pricing varies less than tirzepatide pricing globally because the patent expiration is closer and generic competition is starting in some markets.

US: US GLP-1 telehealth May 2026 covers semaglutide alongside tirzepatide. Wegovy is the most-stocked GLP-1 in US private telehealth.

Bangkok / Thailand: Wegovy / Mounjaro / Zepbound in Bangkok 2026 is the brand-by-brand snapshot. Bangkok GLP-1 expat playbook for the strategy. The Bangkok GLP-1 starter hub for everything Bangkok-related in one place.

Singapore: Singapore GLP-1 buyer's guide 2026, Singapore May 2026 update. Wegovy is the more reliably stocked option in Singapore than in Thailand.

UK: UK GLP-1 buyer's guide, May 2026 NHS update. The NHS-vs-private decision tree is more developed for Wegovy than for Mounjaro.

Australia: Australia GLP-1 buyer's guide May 2026. The Aussie market is structurally cleaner than the US.

Vietnam, Bali, UAE, Hong Kong, New Zealand: Vietnam, Bali, UAE, Hong Kong, New Zealand.

You're already on it and have questions

Most of the catalog's "while on it" posts are written for tirzepatide because the search volume is higher there, but most of the same content applies to semaglutide.

GLP-1 side effects honest list covers the cross-drug picture.

GLP-1 alcohol 2026 update is the latest alcohol-reduction data and applies to semaglutide as well as tirzepatide.

GLP-1 and morning workouts on training while on the drug.

GLP-1 and mental health on the mood-change discourse and what the data actually shows.

The plateau at month six on what to do (and not do) when the scale stops moving. The plateau pattern is similar across drugs.

Eight-week quit window on the specific physiological window worth understanding.

The maintenance dose no one explains on tapering without quitting. Maintenance dosing is more developed for semaglutide than for tirzepatide because semaglutide has been on the market longer.

You're worried about supply

Wegovy supply has been variable since launch. Ozempic supply tightened in 2023 when off-label weight-loss prescribing exploded; that has eased somewhat as Wegovy and Mounjaro absorbed the demand.

Peptide pulse May 2026 is the current cross-region supply snapshot. The Bangkok supply digest for the regional micro-view.

For brand authentication, how to spot a fake tirzepatide pen covers the same principles for any GLP-1 pen authentication.

You're comparing it to the next-generation drugs

The semaglutide vs tirzepatide debate is also a debate about whether to wait for the next molecule.

Retatrutide phase 3 update 2026 covers the GLP-1 + GIP + glucagon triple agonist that's currently in phase 3.

Retatrutide explained is the plain-language version.

Semaglutide / tirzepatide / retatrutide 2026 covers all three in one comparison.

FDA horizon: six peptides 2026-2028 is the broader horizon piece. Orforglipron (oral, small molecule) is the relevant near-term semaglutide-class alternative now FDA approved as Foundayo.

For microdose conversations, microdose GLP-1: what the trial data actually shows is the honest read on a topic where semaglutide has the most published microdose data of any GLP-1.

You're stopping (or thinking about it)

What you keep when you stop tirzepatide is written for tirzepatide but the rebound dynamics are similar for semaglutide. STEP-4 (the semaglutide withdrawal trial) is the data underpinning much of the rebound conversation.

When to pause your GLP-1 covers the medical situations where pausing is appropriate.

Comparing semaglutide to alternative classes

Bariatric surgery vs GLP-1 is partial coverage; the deeper question of when each path makes sense is largely out of scope for the blog and lives more in the methodology + Q&A surfaces.

For the comparison to non-pharmacological approaches, the catalog is intentionally light. The blog covers the drug; reader email asking about lifestyle alternatives gets pointed to other sources.

Where to go from here

If you're new to GLP-1s and choosing between Wegovy and tirzepatide, read the semaglutide-vs-tirzepatide post and one regional buyer's guide.

If you're on Wegovy and the supply at your usual pharmacy has wavered, the regional pulse posts are where the current state is.

If you're comparing routes of administration (injection vs Rybelsus oral vs the new oral Wegovy), reader email is the most reliable source right now; the blog is light on Rybelsus-specific content because the population taking it is small.

The Panya catalog updates roughly weekly. To flag a stale post or a missing topic, editor@panya.health is the address.

Common questions

What's the difference between Wegovy, Ozempic, and Rybelsus?

Same molecule, different products. Wegovy is the high-dose injectable for weight management (up to 2.4mg weekly). Ozempic is the lower-dose injectable for type 2 diabetes (up to 2.0mg weekly). Rybelsus is the daily oral pill for T2D, requiring fasting administration. Oral Wegovy (25mg daily) launched in early 2026 for weight management.

Should I switch from semaglutide to tirzepatide?

If you've plateaued at the maintenance dose for 3+ months, tirzepatide will likely give another 5-10% loss on top. If you're tolerating semaglutide well and progressing, switching isn't necessary. The decision depends on plateau status and side-effect profile.

Is generic semaglutide available?

Not in major regulated markets as of mid-2026. Patent expiration timelines vary by region; meaningful generic availability isn't expected until 2031+ in the US. Some regional markets have alternatives via different regulatory pathways.

Can I take semaglutide while pregnant?

No. Semaglutide is contraindicated in pregnancy. Discontinue at least 2 months before planned conception. If you become pregnant while on semaglutide, contact your prescriber immediately for transition guidance.

What insurance covers Wegovy in the US?

US insurance varies. Some plans cover Wegovy for weight loss with prior authorization (BMI 30+, sometimes BMI 27+ with comorbidities). Some plans don't cover GLP-1s for weight loss at all. The Inflation Reduction Act and Medicare coverage rules continue to shift the landscape.